JOURNAL READING

Pembimbing : dr. Hemi Sinorita Sp.PD KEMD

Presentan : Irmawati Suling
Background
Aims
Methode
 Intervention and Procedures

Vitamin D 2.5 tahun Primary outcome

(4000 IU) 3 mo 6 mo 12 mo 24 mo
New onset DM

2.5 tahun Primary outcome

PLACEBO 3 mo 6 mo 12 mo 24 mo New onset DM

Laboratory testing
-Calcium serum
-Creatinin serum
-FPG
-HbA1c
Flow of participants in per‐protocol
analysis.
RESULT
 Interpretasi :
Pada kelompok uji pemberian Vit D
dapat mengurangi resiko T2D
sebesar 12% (estimasi HR : 0.88)
dibandingkan kelompok plasebo.
DISCUSSION
CONT...
CONT...
 CONCLUSION

In conclusion, persons at high risk for type T2D not selected for vitamin D
insufficiency, vitamin D3 supplementation at a dose of 4000 IU/day did not
result in a significantly lower risk of diabetes than placebo.
CRITICAL APRAISAL
Population: Adults with prediabetes
Intervention: vitamin D3 supplementation at a dose of 4000 IU
Comparison : Placebo
Outcome: New onset Diabetes tipe 2

This randomized, double-blind, placebo-controlled clinical

trial evaluated the safety and efficacy of oral administration
of vitamin D3 (cholecalciferol; 4000 IU per day)
All th authors vouch for the accuracy an
completeness of the data and for the fidelity of th
trial to the protocol. They also contributed to th
interpretation of the results and the preparation
review, and approval of the manuscript and mad
the the decision to submit the manuscript fo
publication.
 Bisa diaplikasikan karena saat ini
obat sudah tersedia di Indonesia
(colecalciferol)

Harga 4000/tablet
TERIMA KASIH
BIOSINTESIS VITAMIN D